Summary
Preclinical safety studies with biotechnology products are not only performed for regulatory purposes, but should first and foremost provide information about the potential toxic effects in patients. The initial toxicological experience, using standard testing procedures developed for drugs of small molecular weight, often gave disappointing results, and the development of antibodies against the heterologous products cast doubt upon the validity of the testing approach.
In order to assess the safety of new biotechnology products, compounds must be looked at on a case by case basis. Exaggerated pharmacodynamic effects are often responsible for the major toxicological problems. For some compounds, ‘intrinsic toxicity’, i.e adverse effects due to the molecule per se, may play a role. With others, ‘biological toxicity’, i.e. the activation of physiological processes such as antigen-antibody interaction, release of mediators and cytokines, or initiation of the arachidonic acid-prostaglandin cascade, may be the cause of the observed adverse effects. Examples are given that show the importance of a good understanding of the biological mechanisms of action of toxicity observed in animals and in patients.
Similar content being viewed by others
References
Anderson LC. Safety evaluation of recombinant human erythropoietin. American Association of Science Meeting San Francisco, CA, January 1989. Abstract, p. 58, 1989
Anderson TD, Hayes TJ. Toxicity of human recombinant interleukin-2 in rats. Pathologic changes are characterized by marked lymphocytic and eosinophilic proliferation and multisystem involvement. Laboratory Investigation 60: 331–346, 1989
Anderson TD, Hayes TJ, Gately MK, Bontempo JM, Stern LL, et al. Toxicity of human recombinant interleukin-2 in the mouse is mediated by interleukin-activated lymphocytes. Separation of efficacy and toxicity by selective lymphocyte subset depletion. Laboratory Investigation 59: 598–612, 1988
Billings RE, Finkle BS, Hotchkiss A. Safety assessment of activase (recombinant human tissue plasminogen activator). American Association of Science Meeting San Francisco, CA, January 1989. Abstract, p. 58, 1989
Bottazzo GF, Pujol-Borrell R, Hanafusa T. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet 2: 1115–1119, 1983
Calvet MC, Gresser I. Interferon enhances the excitability of cultured neurones. Nature 278: 558–560, 1979
Fent K, Zbinden G. Toxicity of interferon and interleukin. Trends in Pharmacological Sciences 8: 100–105, 1987
French Directorate of Pharmacy and Drugs. Recommendation concernant le protocole toxicologique des interferons pour l’obtention d’une autorisation de mise sur le marche. March 12–16, 1984
Gresser I. Interferon-induced disease. In De Maeyer E, Schellekens H (Eds) The biology of the interferon system, p. 363, Elsevier Scientific Publishers, Amsterdam, 1983
Japanese Ministry of Health and Welfare. Notification on application data for rDNA drugs. Notification No 243 of the Pharmaceutical Affairs Bureau, March 30, 1984
Maca RD, Fry GL, Hoak JC. New method for detection and quantitation of circulating platelet aggregates. Microvascular Research 4: 453–457, 1972
Matory YL, Chang AE, Lipford III EH, Braziel R, Hyatt CL, et al. Toxicity of recombinant human interleukin-2 in rats following intravenous infusion. Journal of Biological Response Modifiers 4: 377–390, 1985
Mirro Jr J, Kalwinsky D, Whisnant J, Weck P, Chesney C, et al. Coagulopathy induced by continuous infusion of high doses of human lymphoblastoid interferon. Cancer Treatment Report 69: 315–317, 1985
Panem S, Vilcek J. Antibodies to interferon in man. In De Maeyer E & Schellekens H (Eds) The biology of the interferon system, pp. 369–378, Elsevier Science Publishers BV, Amsterdam, 1983
Remick DG, Kunkel SL. Toxic effects of cytokines in vivo. Laboratory Investigation 60: 317–319, 1989
Rohatiner AZS, Prior PF, Burton AC, Smith AT, Balkwill FR, et al. Central nervous system toxicity of interferon. British Journal of Cancer 47: 419–422, 1983
Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, et al. Observations on the systemic administration of autologous lymphokine-activated cells and recombinant interleukin-2 to patients with metastatic cancer. New England Journal of Medicine 313: 1485–1492, 1985
Schellekens H, v.d. Meide PH. Animal studies with interferon. In De Maeyer E & Schellekens H (Eds) The biology of the interferon system, pp. 409–418, Elsevier Science Publishers BV Amsterdam, 1983
Schellekens H, de Reus A, v.d. Meide PH. The chimpanzee as a model to test the side effects of human interferons. Journal of Medical Primatology 13: 235–245, 1984
Scott GM. Interferon: pharmacokinetics and toxicity. Philosophical Transactions of the Royal Society London B 299: 91–107, 1982
Sergiescu D, Cerutti I, Efthymiou E, Kahan A, Chany C. Adverse effects of interferon treatment on the life span of NZB mice. Biomedicine 31: 48–51, 1979
Skoskievicz MJ, Colvin RB, Schneeberger EE, Russell PS. Widespread and selective induction of major histocompatibility complex-determined antigens in vivo by gamma interferon. Journal of Experimental Medicine 162: 1645–1664, 1985
Sondel PM, Kohler PC, Hank JA, Moore KH, Rosenthal NS, et al. Clinical and immunological effects of recombinant interleukin-2 given by repetitive weekly cycles to patients with cancer. Cancer Research 48: 2561–2567, 1988
Sosman JA, Kohler PC, Hank JA, Moore KA, Bechhofer R, et al. Repetitive weekly cycles of interleukin-2. II. Clinical and immunological effects of dose, schedule and addition of indomethacin. Journal of the National Cancer Institute 80: 1451–1461, 1988
Teelmann K, Hohbach C, Lehmann H. Preclinical safety testing of species-specific proteins produced with recombinant DNA-techniques. Archives of Toxicology 59: 195–200, 1986
Todd JA, Acha-Orbea H, Bell JI, Chao N, Fronek Z, et al. A molecular basis for MHC class II-associated autoimmunity. Science 240: 1003–1009, 1988
Velcovsky HG, Federlin KF. Insulin-specific IgG and IgE antibody response in type I diabetic subjects exclusively treated with human insulin (recombinant DNA). Diabetes Care 5 (Suppl. 2): 126–128, 1982
Zbinden G. Biotechnology products intended for human use, toxicological targets and research strategies. In Graham CE (Ed.) Preclinical safety of biotechnology products intended for human use, pp. 143–159, Alan R. Liss, Inc., New York, 1987
Zbinden G. Effects of recombinant human alpha interferon in a rodent cardiotoxicity model. Toxicology Letters, in press
Zbinden G, Grimm L. Thrombogenic effects of xenobiotics. Archives of Toxicology (Suppl. 8): 131–141, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zbinden, G. Safety Evaluation of Biotechnology Products. Drug-Safety 5 (Suppl 1), 58–64 (1990). https://doi.org/10.2165/00002018-199000051-00009
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199000051-00009